Paris-based drugmaker Sanofi is exploring a potential acquisition of cancer drugmaker Mirati Therapeutics, Bloomberg News reported on Thursday citing people familiar with the matter. Deliberations are ongoing and there is no certainty they will result in an agreement, the report said, adding that Mirati could also attract interest from other suitors.
FDA GREENLIGHTS TARGETED THERAPY FOR LUNG CANCER MUTATION CLICK HERE TO GET THE FOX NEWS APP A Sanofi spokesperson responded to a Reuters' request saying the company does not comment on market rumors. Mirati, whose shares rose 25.48% to $53.83, did not immediately respond to Reuters' request for a comment. Mirati's lung cancer drug, Krazati, had received the U.S. health regulator's nod in December to treat adults with advanced lung cancer.
مصر أحدث الأخبار, مصر عناوين
Similar News:يمكنك أيضًا قراءة قصص إخبارية مشابهة لهذه التي قمنا بجمعها من مصادر إخبارية أخرى.
Sanofi to explore acquisition of cancer drugmaker Mirati- Bloomberg NewsSanofi to explore acquisition of cancer drugmaker Mirati- Bloomberg News
اقرأ أكثر »
Stocks making the biggest moves midday: Rivian, Orchard Therapeutics, Lamb Weston and moreThese are the stocks posting the largest moves in midday trading.
اقرأ أكثر »
Clorox stock falls after detailing cyberattack hit and other stocks on the moveOrchard Therapeutics, Clorox and Rivian Automotive stocks were on the move.
اقرأ أكثر »
Clorox's stock falls after cyberattack hit, and other stocks on the moveShares of Orchard Therapeutics, Clorox and Rivian Automotive were on the move
اقرأ أكثر »